Cellular mRNA expression of interferon-gamma (IFN-γ), IL-4 and transforming growth factor-beta (TGF-β) in rats nasally tolerized against experimental autoimmune myasthenia gravis (EAMG)

Clinical and Experimental Immunology

Volumn 104, Issue 3, 1996, Pages 509-516

  Ma, C G ^a   Zhang, G X ^a   Xiao, B G ^a   Link, H ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Experimental autoimmune myasthenia gravis; IFN ; IL 4; Tolerance; Transforming growth factor beta

Indexed keywords

CHOLINERGIC RECEPTOR ANTIBODY; GAMMA INTERFERON; INTERLEUKIN 4; MESSENGER RNA; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOIMMUNITY; CONTROLLED STUDY; ETIOLOGY; FEMALE; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; IN SITU HYBRIDIZATION; MYASTHENIA GRAVIS; NONHUMAN; PRIORITY JOURNAL; RAT; T LYMPHOCYTE;

EID: 0030048452     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.1996.50755.x     Document Type: Article

References (36)

1. Weiner HL, Friedman A, Miller A et al. Oral tolerance: immunologic mechanisms and treatment of murine and human organ specific autoimmune diseases by oral administration of autoantigens. Annu Rev Immunol 1994; 12:809-37.
2. Miller A, Lider O, Roberts AB, Sporn MB, Weiner HL. Suppressor T cells generated by oral tolerization to myelin basic protein suppress both in vitro and in vivo immune responses by the release of transforming growth factor β after antigen-specific triggering. Proc Natl Acad Sci USA 1992; 89:421-5.
3. Lindstrom J, Shelton D, Fujii Y. Myasthenia gravis. Adv Immunol 1988; 42:233-85.
4. Hohlfeld R, Conti-Tronconi B, Kalies J, Bertrams I, Toyka KV. Genetic restriction of autoreactive acetylcholine receptor-specific T lymphocytes in myasthenia gravis. J Immunol 1985; 135:2393-9.
5. + T cells suppresses experimental autoimmune myasthenia gravis in Lewis rats. Eur J Immunol 1995; 25:1191-8.
6. Wang ZY, Link H, Qiao J, Olsson T, Huang WX. B cell autoimmunity to acetylcholine receptor and its subunits in Lewis rats over the course of experimental autoimmune myasthenia gravis. J Neuroimmunol 1993; 45:103-12.
7. Wang ZY, Qiao J, Melms A, Link H. T cell reactivity to acetylcholine receptor in rats orally tolerized against experimental autoimmune myasthenia gravis. Cell Immunol 1994; 152:394-404.
8. Wang ZY, Link H, Ljungdahl Å et al. Induction of interferon-γ, interleukin-4 and transforming growth factor-β in rats orally tolerized against experimental autoimmune myasthenia gravis. Cell Immunol 1994; 157:353-68.
9. Okumura S, McIntosh K, Drachman DB. Oral administration of acetylcholine receptor: effects on experimental myasthenia gravis. Ann Neurol 1994; 36:704-13.
10. Ma CG, Zhang GX, Xiao BG, Link J, Olsson T, Link H. Suppression of experimental autoimmune myasthenia gravis by nasal administration of acetylcholine receptor. J Neuroimmunol 1995; 58:51-60.
11. Deibler GE, Martensson RE, Kies MV. Large scale preparation of myelin basic protein from central nervous tissue of several mamalian species. Prep Biochem 1972; 2:139-65.
12. Link J, Söderström M, Ljungdahl Å et al. Organ-specific autoantigens induce interferon-γ and interleukin-4 mRNA expression in mononuclear cells in multiple sclerosis and myasthenia gravis. Neurology 1994; 44:728-34.
13. Pullen GR, Fitzgerald MG, Hosking CS. Antibody avidity determination by ELISA using thiocynate elution. J Immunol Methods 1986; 86:83-87.
14. Vrethem M, Ekerfelt C, Ernerudh J. Avidity distribution of antibodies against peripheral nerve myelin in patients with polyneuropathy associated with IgM monoclonal gammopathy and in healthy controls. J Neurol Sci 1995; 131:190-9.
15. Christadoss P, Lindstrom J, Munro S, Talal N. Muscle acetylcholine receptor loss in murine experimental autoimmune myasthenia gravis: correlated with cellular, humoral and clinical responses. J Neuroimmunol 1985; 8:29-41.
16. Zhang GX, Ma CG, Xiao BG, Bakheit M, Ljungdahl A, Olsson T, Link H. Suppression of experimental autoimmune myasthenia gravis after CD8 depletion is associated with decreased IFN-γ and IL-4. Scand J Immunol 1995; 42:457-65.
17. Link H, Olsson O, Sun JB et al. Acetylcholine receptor-reactive T and B cells in myasthenia gravis and controls. J Clin Invest 1991; 87:2191-6.
18. Simmons RD, Willenhorg DO. Direct injection of cytokines into the spinal cord causes autoimmune encephalomyelitis-like inflammation. J Neurol Sci 1990; 100:37-42.
19. Hamel CP, Detrick B, Hooks JJ. Evaluation of Ia expression in rat ovular tissues following inoculation with interferon-gamma. Exp Eye Res 1990; 50:173-81.
20. Schattner A. Lymphokines in uutoimmunity - a critical review. Clin Immunol Immunopathol 1994; 70:177-89.
21. Gu D, Wogensen L, Calcutt NA et al. Myasthenia gravis-like syndrome induced by expression of interferon γ in the neuromuscular junction. J Exp Med 1995; 181:547-57.
22. Skoskiewicz MH, Callin RB, Sternberger EE, Russel PS. Widespread and selective induction of major histocompatibility complex determined antigens in vivo by γ interferon. J Exp Med 1985; 162:1645-64.
23. Sidman CL, Maxwell JD, Schultz LD, Gray WP, Johnson HM. γ-Interferon is one of several direct B cell-maturing lymphokines. Nature 1984; 309:801-4.
24. Collart MA, Belin J, Vassalli D, de Kossodo S, Vassalli P. Gamma-interferon enhances macrophage transcription of the tumor necrosis factor/cachectin, interleukin-1, and urokinase genes, which are controlled by short-lived repressors. J Exp Med 1986; 164:2113-8.
25. Nakano S, Engel AG. Myasthenia gravis: quantitative immunocytochemical analysis of inflammatory cells and detection of complement membrane attack complex at the end-plate in 30 patients. Neurology 1993; 43:1167-72.
26. Finkelman PD, Holmes J. Lymphokine control of in vivo immunoglobulin isotype selection. Annu Rev Immunol 1990; 8:303-33.
27. Link J, Navikas V, Yu M, Fredrikson S, Osterman PO, Link H. Augmented interferon-γ, interleukin-4 and transforming growth factor-β mRNA expression in blood mononuclear cells in myasthenia gravis. J Neuroimmunol 1994; 51:185-92.
28. Sasaki H, Pollard RB, Schmitt D, Suzuki K. Transforming growth factor-β in the regulation of the immune response. Clin Immunol Immunopathol 1992; 65:1-9.
29. Kehrl JH, Thevenin C, Rieckmann P, Fauei AS. Transforming growth factor-β suppresses human B lymphocyte Ig production by inhibiting synthesis and the switch from the membrane form to the secreted form of Ig mRNA. J Immunol 1991; 146:4016-23.
30. Kehrl JH, Wakefield LD, Roberts AB et al. Production of transforming growth factor β by human T lymphocytes and its potential role in the regulation of T cell growth. J Exp Med 1986; 163:1037 50.
31. Kim KJ, Abrams J, Alphonso M. Role of endogenously produced interleukin-6 as a second signal in murine thymocyte proliferation induced by multiple cytokines: regulatory effects of transforming growth factor-β1. Cell Immunol 1990; 131:261-8.
32. Stevens DB, Gould KE, Swanborg RH. Transforming growth factor-β1 inhibits tumor necrosis factor-α/lymphotoxin production and adoptive transfer of disease by effector cells of autoimmune encephalomyelitis. J Neuroimmunol 1994; 51:7-83.
33. Link J, He B, Navikas V, Palasik W, Fredrikson S, Söderström M, Link H. TGF-β suppresses autoantigen-induced expression of proinflammatory cytokines but not IL-10 in multiple sclerosis and myasthema gravis. J Neuroimmunol 1995; 58:21-35.
34. Czarniecki CW, Chiu HH, Wong GW, McCabe SM, Palladino MA. Transforming growth factor-β1 modulates the expression of class II histocompatibility antigens on human cells. J Immunol 1988; 140:4217-23.
35. Gamble JR, Vadas MA. Endothelial cell adhesiveness for human T lymphocytes is inhibited by transforming growth factor-β. J Immunol 1991; 146:1149-54.
36. Link J, Fredrikson S, Söderström M, Olsson T, Höjeberg B, Ljungdahl Å, Link H. Organ-specific autoantigens induce transforming growth factor-β mRNA expression in mononuclear cells in multiple sclerosis and myasthenia gravis. Ann Neurol 1994; 35:197-203.